TG Therapeutics (TGTX) Stock

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that it has been named the top company on the Deloitte Technology Fast 500™. This ranking highlights the 500 fastest-growing companies in sectors like technology, media, telecommunications, life sciences, fintech, and energy tech in North America, and it is now in its 30th year.

TG Therapeutics, Inc. had a small improvement in their Q3 results and increased their full-year sales forecast for Briumvi by $7.5 million at the midpoint. Although the results were a bit disappointing, they met the company's expectations for a weaker Q3. Now, we look forward to key updates in early 2025, including preliminary Q4 sales for Briumvi, guidance for 2025, and initial trial results for subcutaneous Briumvi.

TG Therapeutics, Inc. (NASDAQ:TGTX) will hold its Q3 2024 earnings conference call on November 4, 2024, at 8:30 AM ET. The call will feature company representatives including Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Participants from various financial institutions will also join the call, including Ed White from H.C. Wainwright and Michael DiFiore from Evercore ISI.

TG Therapeutics (TGTX) reported quarterly earnings of $0.02 per share, which is lower than the Zacks Consensus Estimate of $0.04 per share. This is a decrease compared to earnings of $0.73 per share from the same period last year.

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that they will hold a conference call on Monday, November 4, 2024, at 8:30 AM ET. The call will cover the results for the third quarter of 2024 and share the company's outlook for the rest of the year. Michael S.

In the fifth year of treatment with BRIUMVI, the annual relapse rate was 0.020, which means that a patient would experience one relapse every 50 years of treatment.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced its schedule for upcoming data presentations. These will showcase findings from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial, which assess BRIUMVI® (ublituximab-xiiy) for patients with relapsing forms of multiple sclerosis (RMS). The presentations will take place at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting in Copenhagen, Denmark, from September 18 to 20, 2024, and the abstracts are now available online.

TG Therapeutics surpassed analysts' expectations for the second quarter, reporting Briumvi net sales of $72.6 million and total revenues of $73.5 million. They achieved positive cash flow earlier than I anticipated and increased their full-year revenue guidance by $15 million at the midpoint. Additionally, TG obtained a new $250 million credit facility to replace the old one and plans to use $100 million for share buybacks.

TG Therapeutics (TGTX) reported quarterly earnings of $0.04 per share, which is better than the Zacks Consensus Estimate that predicted a loss of $0.04 per share. This is an improvement compared to a loss of $0.34 per share from the same period last year.